Zimmer Biomet Holdings, Inc.

Company Overview

Business Model: Zimmer Biomet is a global medical technology leader focused on maximizing mobility and improving health. The Company designs, manufactures, and markets a comprehensive portfolio of orthopedic reconstructive products; sports medicine, biologics, extremities, and trauma products; craniomaxillofacial and thoracic (“CMFT”) products; bone cement; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics, and artificial intelligence. Zimmer Biomet collaborates with healthcare professionals globally to advance innovation, with products and solutions treating disorders of, or injuries to, bones, joints, or supporting soft tissues. Primary customers include orthopedic surgeons, neurosurgeons, other specialists, healthcare institutions, stocking distributors, healthcare dealers, and healthcare purchasing organizations. Approximately 85% of net sales in 2025 were consignment sales, with revenue generally recognized upon implantation or when title passes upon shipment.

Market Position: Operating in a highly competitive orthopedics and broader musculoskeletal care industry, Zimmer Biomet positions itself as a global medical technology leader. Competition is primarily driven by technology, innovation, quality, reputation, customer service, and pricing. Key competitors in knees, hips, and S.E.T. products include Johnson & Johnson MedTech, Stryker Corporation, and Smith & Nephew plc. The Company's future success is dependent on its ability to develop and improve new and existing products and technologies. The ZBEdge Platform, which connects robotic and digital technologies, is a strategic offering designed to deliver insights to surgeons.

Recent Strategic Developments:

• Acquisitions: Completed the acquisition of Paragon 28, Inc. on April 21, 2025, a medical device company specializing in foot and ankle orthopedics, to increase market share in this faster-growing segment. Acquired Monogram Technologies Inc. on October 7, 2025, an orthopedic robotics company, to enhance its suite of robotic technologies, enabling solutions and analytics for pre-, intra-, and post-operative surgical needs.
• Sales Force Transformation: Initiated a multi-year program to convert substantial portions of its U.S. sales force from independent sales agents to employees and is increasing product category specialization. Similar changes are being implemented in certain international markets to optimize commercial strategies.
• Restructuring and Portfolio Rationalization: Launched a series of restructuring programs (2025, 2023, 2021, 2019) aimed at reducing costs, improving efficiency, and prioritizing investments in high-growth operations. The Company is also rationalizing its product portfolio to streamline operations and enhance focus on strategic offerings.
• Innovation Focus: Broadening product offerings and exploring new technologies, including artificial intelligence and machine learning, for various applications.

Geographic Footprint: Zimmer Biomet sells products in over 100 countries, with approximately 42% of its 2025 net sales derived from outside the U.S. The Company operates through three regional segments:

• Americas: The largest segment, primarily comprising the U.S. (approximately 95% of regional net sales in 2025), along with other North, Central, and South American markets.
• Europe, Middle East and Africa (EMEA): The second largest segment, with France, Germany, Italy, Spain, and the United Kingdom collectively accounting for approximately 50% of regional net sales in 2025.
• Asia Pacific: Japan is the largest market within this segment, representing approximately 50% of the region’s net sales in 2025. The Company maintains primary research and development facilities in the U.S. (Warsaw, Indiana; Denver, Colorado; Jacksonville, Florida; Austin, Texas), Canada (Montreal, Quebec), Switzerland (Zug), and China (Beijing). It has approximately 25 manufacturing locations globally, with significant sites in the U.S., Switzerland, Ireland, and China, and operates large, centralized warehouses in the U.S. and the Netherlands.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 61.6%
• Operating Margin: 13.3%
• Net Margin: 8.6%

Investment in Growth:

• R&D Expenditure: $458.5 million (5.6% of revenue)
• Capital Expenditures: $525.0 million
• Strategic Investments:
  • Acquisition of Paragon 28, Inc.: $1,276.5 million (fair value of consideration transferred, including contingent consideration).
  • Acquisition of Monogram Technologies Inc.: $377.5 million (fair value of consideration transferred, including contingent consideration).
  • Acquisition of intangible assets (ownership rights or access to technologies): $52.4 million.

Business Segment Analysis

Americas

Financial Performance:

• Revenue: $5,144.6 million (+7.3% YoY)
• Operating Margin: 51.4% (vs. 53.7% in 2024)
• Key Growth Drivers: The acquisition of Paragon 28, Inc. (contributing 3.6% to U.S. net sales growth), market growth in Knees, Hips, and S.E.T. product categories, new product introductions, recovery from prior year operational challenges due to an ERP system implementation, and opportunistic end-of-year customer purchases and capital sales.

Product Portfolio: The segment sells a comprehensive range of products including Knees, Hips, S.E.T. (Sports Medicine, Extremities, Trauma, Craniomaxillofacial and Thoracic), and Technology & Data, Bone Cement and Surgical products.

Market Dynamics: The U.S. market accounts for approximately 95% of the segment's net sales. The Company is undergoing a multi-year initiative to convert a substantial portion of its U.S. sales force from independent agents to employees and is increasing product category specialization. Group purchasing organizations are key partners, with contracts typically lasting three years.

Sub-segment Breakdown:

• Americas Orthopedics: Includes goodwill from the Paragon 28, Inc. and Monogram Technologies Inc. acquisitions.
• Americas CMFT: Includes goodwill from a 2024 acquisition.

Europe, Middle East and Africa (EMEA)

Financial Performance:

• Revenue: $1,828.8 million (+8.1% YoY)
• Operating Margin: 32.5% (vs. 35.1% in 2024)
• Key Growth Drivers: The acquisition of Paragon 28, Inc. (contributing 1.1% to International net sales growth), market growth, and positive foreign currency exchange rates (contributing 1.8% to International net sales growth).

Product Portfolio: The segment offers Knees, Hips, S.E.T., and Technology & Data, Bone Cement and Surgical products.

Market Dynamics: France, Germany, Italy, Spain, and the United Kingdom collectively represent approximately 50% of the region's net sales. Government-sponsored healthcare systems in most European countries influence healthcare spending and sales. The sales force comprises direct sales associates, commissioned agents, and independent distributors.

Asia Pacific

Financial Performance:

• Revenue: $1,258.1 million (+5.5% YoY)
• Operating Margin: 35.5% (vs. 38.7% in 2024)
• Key Growth Drivers: The acquisition of Paragon 28, Inc. (contributing 1.1% to International net sales growth), market growth, and positive foreign currency exchange rates (contributing 1.8% to International net sales growth).

Product Portfolio: The segment provides Knees, Hips, S.E.T., and Technology & Data, Bone Cement and Surgical products.

Market Dynamics: Japan is the largest market in this segment, accounting for approximately 50% of regional net sales. The Company utilizes a network of dealers and sales associates. Government-sponsored healthcare is prevalent in certain countries within the region.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: $487.0 million
• Dividend Payments: $190.3 million
• Future Capital Return Commitments: On February 9, 2026, the Board of Directors authorized a new $1.5 billion share repurchase program with no expiration date, replacing the prior program which had $770.2 million remaining.

Balance Sheet Position:

• Cash and Equivalents: $591.9 million (as of December 31, 2025)
• Total Debt: $7,519.1 million (as of December 31, 2025)
• Net Cash Position: -$6,927.2 million (Net Debt)
• Debt Maturity Profile: $587.1 million in current debt (2.425% Euro Notes due 2026) maturing on December 13, 2026. Other senior notes mature between 2027 and 2045.

Cash Flow Generation:

• Operating Cash Flow: $1,697.1 million (2025)
• Free Cash Flow: $1,172.1 million (Operating Cash Flow less Capital Expenditures)

Operational Excellence

Production & Service Model: Zimmer Biomet manufactures products at various global sites and strategically outsources some manufacturing to qualified suppliers. Its manufacturing operations are designed around a cellular concept, implementing Lean and Six Sigma methodologies for continuous improvement in product quality, lead time reduction, and capacity optimization. The Company cross-trains many employees and continuously evaluates in-sourcing and outsourcing opportunities. Manufacturing processes have been improved through computer-assisted robots, multi-axis grinders, automated inspection, and state-of-the-art equipment to optimize quality systems and offset inflationary costs.

Supply Chain Architecture: The Company uses a diverse range of raw materials and components, purchasing them from external suppliers. Certain materials, components, and outsourced activities are sourced from a single or limited number of suppliers due to quality, availability, cost, or regulatory requirements. Zimmer Biomet works closely with suppliers to ensure continuity of supply, quality, and reliability. Product sterilization is performed using a mix of internal resources and contract sterilizers.

Key Suppliers & Partners:

• Raw Materials: Cobalt chrome, titanium, tantalum, polymer, and sterile packaging.
• Manufacturing Partners: Qualified third-party suppliers for outsourced components and activities.
• Sterilization Partners: Contract sterilizers for product sterilization services.

Facility Network:

• Manufacturing: Operates approximately 25 manufacturing locations globally, with significant sites in the U.S., Switzerland, Ireland, and China. U.S. facilities are primarily owned, while international facilities are a mix of owned and leased.
• Research & Development: Primary R&D facilities are located in Warsaw, Indiana; Montreal, Quebec, Canada; Denver, Colorado; Jacksonville, Florida; Austin, Texas; Zug, Switzerland; and Beijing, China.
• Distribution: Utilizes large, centralized warehouses in the U.S. and the Netherlands, supplemented by smaller, market-specific distribution facilities in the U.S. and other countries with a direct sales presence.

Operational Metrics:

• Total Recordable Incident Rate: 0.22 (2025)
• Lost Time Incident Rate: 0.10 (2025)

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: Directly to healthcare institutions such as hospitals and ambulatory surgery centers.
• Channel Partners: Through stocking distributors and healthcare dealers.
• Sales Force: Employs a network of sales associates, sales managers, and support personnel, including both employees and independent distributors/agencies. Significant investment is made in training sales associates to provide technical support and product information to surgeons. A multi-year initiative is underway to convert a substantial portion of the U.S. sales force from independent agents to employees, alongside increasing product category specialization.
• Digital Platforms: Leverages the ZBEdge Platform, which integrates robotic and digital technologies to collect data and provide insights to surgeons.

Customer Portfolio: Enterprise Customers: The customer base includes orthopedic surgeons, neurosurgeons, other specialists, healthcare institutions, stocking distributors, healthcare dealers, and healthcare purchasing organizations.

• Customer Concentration: No single customer accounted for more than 2% of net sales in 2025, indicating a diversified customer base.
• Strategic Partnerships: Engages with group purchasing organizations in the Americas, offering volume discounts to affiliated healthcare institutions.

Geographic Revenue Distribution:

• United States: 57.9% of total revenue ($4,764.0 million)
• International: 42.1% of total revenue ($3,467.5 million)
• Growth Markets: The Company plans to continue pursuing growth opportunities in international markets, including emerging markets.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The orthopedics and broader musculoskeletal care industry is highly competitive. Market dynamics are influenced by an aging and active global population, technological advancements, and data demonstrating positive clinical outcomes. The industry also faces evolving customer needs, changing demographics, and shifts in surgical philosophies and industry standards. Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Johnson & Johnson MedTech (formerly the DePuy Synthes Companies of Johnson & Johnson)
• Stryker Corporation
• Smith & Nephew plc
• Numerous smaller competitors focusing on specific subsegments of the industry.

Emerging Competitive Threats: The Company faces threats from new market entrants, disruptive technologies, and alternative solutions such as pharmaceutical and other therapies. Competitors may also possess superior capabilities to serve specific sites of care, including hospitals, ambulatory surgical centers, and doctors' offices.

Competitive Response Strategy: Zimmer Biomet's strategy includes continuous development and improvement of new and existing products and technologies, broadening its offerings, and exploring advanced technologies like AI and machine learning. The Company is also transforming its sales and distribution networks in the U.S. and other markets, implementing restructuring programs to enhance efficiency, and rationalizing its product portfolio to focus on strategic offerings. Strategic acquisitions, such as Paragon 28, Inc. and Monogram Technologies Inc., are used to expand market share and portfolio capabilities.

Risk Assessment Framework

Strategic & Market Risks

• Market Dynamics: Highly competitive environment, dependence on new product development and innovation, changes in customer demand, product obsolescence, emergence of alternative therapies, and shifts in product category or regional sales mix.
• Technology Disruption: Risk of products becoming obsolete due to technological advances by competitors, and challenges related to emerging FDA oversight and regulation of artificial intelligence, machine learning, and software as a medical device, including potential inaccuracies or errors.

Operational & Execution Risks

• Supply Chain Vulnerabilities: Dependence on a limited number of suppliers for key raw materials, components, and outsourced activities, with potential for disruptions in supply (e.g., due to supplier bankruptcy or regulatory restrictions on sterilization methods). Inability to establish alternative suppliers in a timely or cost-effective manner.
• Capacity Constraints: Manufacturing interruptions due to damage to facilities, cyber attacks, compliance issues (QSR/GMP), equipment malfunction, worker absences, trade impediments, or international conflicts.
• ERP System Challenges: Unanticipated challenges during the 2024 Americas ERP transition disrupted order fulfillment, product distribution, customer demand, invoicing, and increased costs, leading to potential loss of customers and sales. Future disruptions from ERP system updates remain a risk.
• Sales Force Transformation: Risks associated with the multi-year initiative to convert U.S. sales force to employees and changes in international go-to-market models, including operational disruptions, increased costs, reduced sales, loss of key sales personnel, and diminished sales effectiveness.
• Product Portfolio Rationalization: Potential for loss of product breadth, disruption in customer relationships, reduced sales in affected categories, transitional inefficiencies, inventory imbalances, and asset impairments.

Financial & Regulatory Risks

• Market & Financial Risks: Declining or reduced reimbursement levels from third-party payors, cost containment measures (e.g., group purchasing organizations, China's volume-based procurement, Italy's "Pay Back" law), substantial indebtedness ($7.5 billion total debt as of December 31, 2025), increased borrowing costs due to interest rate fluctuations (e.g., SOFR increases), changes in tax laws (e.g., OECD Pillar 2), additional tax liabilities from examinations and audits (e.g., IRS proposed adjustments for 2013-2015 and 2016-2019), and material impairment of intangible assets (goodwill $9.9 billion, intangible assets $4.7 billion).
• Regulatory & Compliance Risks: Extensive and increasingly stringent government regulation (FDA, EU MDR, UK MDR) affecting product development, manufacturing, marketing, and post-market surveillance. Risks include delays in regulatory approvals, non-compliance penalties, healthcare fraud and abuse laws (False Claims Act, Anti-Kickback Statute), data privacy and security laws (e.g., cross-border data transfers), product liability claims, and intellectual property infringement litigation.

Geopolitical & External Risks

• Geopolitical Exposure: Significant international sales and manufacturing operations (42% of 2025 net sales from outside U.S.) expose the Company to risks from changes in foreign medical reimbursement policies, inconsistent demand in developing markets, foreign regulatory requirements, local product preferences, foreign currency exchange rate fluctuations, inflation, diminished intellectual property protection, foreign exchange controls, labor force instability, and political/social/economic instability (e.g., wars, trade disputes, Red Sea attacks).
• Trade Relations: Adverse effects from tariffs, trade restrictions, embargoes, and sanctions (e.g., U.S. tariff and export controls policies, China's VBP, "buy local" initiatives).
• Sanctions & Export Controls: Compliance requirements and business limitations imposed by U.S. government agencies (Bureau of Industry and Security, OFAC) and other international trade controls.

Innovation & Technology Leadership

Research & Development Focus: Zimmer Biomet maintains extensive research and development activities focused on creating new surgical techniques, including robotic applications, advanced materials, biologics, and product designs. A core strategy is the rapid commercialization of new data solutions, surgical techniques, innovative materials, biologics products, and implant and instrument designs. The Company is actively broadening its offerings and exploring new technologies, such as artificial intelligence and machine learning, for various applications. Primary R&D facilities are located in Warsaw, Indiana; Montreal, Quebec, Canada; Denver, Colorado; Jacksonville, Florida; Austin, Texas; Zug, Switzerland; and Beijing, China. As of December 31, 2025, approximately 2,000 employees were dedicated to R&D worldwide. The Company expects to continue identifying innovative technologies through acquisitions, licensing arrangements, or strategic alliances.

Intellectual Property Portfolio: The Company owns or controls over 6,000 issued patents and patent applications globally, which are crucial to its business success. It also relies on trade secrets, know-how, continuous technological innovation, and licensing opportunities to maintain its competitive position. Proprietary rights are protected through confidentiality agreements. Recent agreements have been entered into to acquire ownership rights or access to various technologies, eliminating future royalty payments.

Technology Partnerships: Zimmer Biomet expects to establish technology licensing arrangements or strategic alliances to further its innovation goals.

Leadership & Governance

Executive Leadership Team

Board Composition: The Audit Committee of the Board of Directors oversees the Company's cybersecurity program and receives periodic assessments from independent third-party experts.

Human Capital Strategy

Workforce Composition:

• Total Employees: Approximately 17,000 worldwide as of December 31, 2025.
• Geographic Distribution: Approximately 7,000 employees are located in the U.S., and approximately 10,000 are located outside of the U.S., primarily across Europe, Japan, and China.
• Skill Mix: The workforce includes approximately 2,000 research and development employees and approximately 6,000 employees dedicated to manufacturing.

Talent Management: Acquisition & Retention: Zimmer Biomet focuses on identifying, attracting, and retaining talent. The Company's employee value proposition includes competitive compensation, benefits, and a supportive culture. Diversity & Development:

• Diversity Metrics: The Company supports eight global employee resource groups (ERGs) with participation representing approximately 15% of its workforce.
• Development Programs: Employee engagement surveys are conducted to inform actions for improving engagement. Frequent and transparent communication through town halls, video messages, and intranet news is utilized.
• Culture & Engagement: The Company's mission to alleviate pain and improve quality of life guides its human capital management policies, emphasizing respect, gratitude, patient safety, quality, integrity, focused resource allocation, fair return, and community contribution.

Environmental & Social Impact: Social Impact Initiatives:

• Community Investment: ERGs receive funding from the Zimmer Biomet Foundation, Inc. to support communities and partnerships aligned with the Company's mission.
• Product Impact: The Company's products and solutions are designed to help millions of people live better lives by treating disorders of, or injuries to, bones, joints, or supporting soft tissues.
• Health, Safety and Wellness: The Company sponsors wellness programs for physical, financial, and mental wellbeing. It maintains a strong focus on workplace health and safety, evidenced by a Total Recordable Incident Rate of 0.22 and a Lost Time Incident Rate of 0.10 in 2025.

Business Cyclicality & Seasonality

Demand Patterns:

• Seasonal Trends: The business exhibits some seasonality, as many products are used in elective procedures. These procedures typically decline during the summer months and tend to increase at the end of the year, often coinciding with patients meeting annual deductibles on health insurance plans.
• Planning & Forecasting: Sales to customers where title passes upon shipment can fluctuate due to large quantity purchases driven by incentives or new product offerings, leading to period-to-period differences in sales. The Company generally does not have firm orders, as most sales occur at the time of an elective procedure.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations: Zimmer Biomet's operations and products are subject to extensive and increasingly stringent government regulation globally, including the U.S. Federal Food, Drug and Cosmetic Act (FDCA) and U.S. Food and Drug Administration (FDA) regulations covering development, manufacturing, marketing, and post-market surveillance. In the European Union, the European Medical Device Regulation (EU MDR) took effect in May 2021, replacing the Medical Device Directive (MDD), imposing significant additional requirements with compliance deadlines in December 2027 or December 2028 depending on device risk class. The UK is also developing its own medical device regulatory framework (UK MDR). The Company's quality management system is certified to ISO 13485 and Medical Device Single Audit Program (MDSAP).

• International Compliance: A global trend towards increased regulatory activity related to medical products and devices is observed.
• Emerging Technologies: New products incorporating artificial intelligence, machine learning, and software as a medical device are subject to evolving FDA oversight and regulation.

Trade & Export Controls:

• Export Restrictions: The Company is subject to foreign trade controls administered by U.S. government agencies, including the Bureau of Industry and Security within the Commerce Department and the Office of Foreign Assets Control (OFAC) within the Treasury Department. Exported medical products must also comply with the regulatory requirements of each destination country.
• Sanctions Compliance: Compliance with sanctions and export controls is required, which can limit business activities in certain countries.

Legal Proceedings: Zimmer Biomet is involved in various legal proceedings, including product liability, intellectual property, and governmental investigations. As of December 31, 2025, accrued litigation liabilities totaled $136.2 million.

• China Sales/Distribution Claims: Displaced or impacted distributors in China have raised legal claims against the Company in connection with its sales and distribution strategy transformation in the region. The outcome of these disputes is uncertain and could materially impact operations in China.
• IRS Proposed Adjustments: The IRS has proposed adjustments for tax years 2013-2015 (primarily related to transfer pricing and profit reallocation between U.S. and Swiss affiliates) and for 2016-2019 (primarily related to U.S. taxation of foreign earnings and profits, potentially resulting in an additional $312 million tax expense). The Company intends to vigorously contest these adjustments.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: 15.1% for 2025 and 12.7% for 2024.
• Effective Tax Rate Drivers (2025): Primarily driven by the foreign rate differential due to lower corporate income tax rates in foreign locations, and a net favorable impact from certain intercompany transactions and restructuring.
• Future Outlook: The Company expects its future effective tax rate to be lower than the U.S. corporate income tax rate of 21.0% due to its mix of earnings between U.S. and foreign locations.
• Puerto Rico: Operations in Puerto Rico benefit from a tax incentive grant set to expire in fiscal year 2026.
• Transition Tax: A remaining current liability of $85.9 million from a one-time tax on the mandatory deemed repatriation of post-1986 untaxed foreign earnings and profits is expected to be fully paid in 2026.

Geographic Tax Planning: The Company generally intends to limit distributions from foreign subsidiaries to avoid significant U.S. tax costs, particularly from previously taxed earnings. However, in 2025, a policy was implemented to repatriate cash reserves from China to the U.S., with appropriate tax impacts recorded.

Tax Reform Impact:

• OECD Pillar 2: The Organisation for Economic Co-operation and Development (OECD) has a framework for a global minimum corporate tax of 15%. While the U.S. has not enacted legislation, certain countries where Zimmer Biomet operates have adopted or are introducing Pillar 2 legislation. Recent administrative guidance (Side-by-Side package) from OECD/G20 introduces simplifications and safe harbors, potentially exempting U.S.-parented groups from certain Pillar 2 top-up taxes.
• U.S. One Big Beautiful Bill Act (OBBBA): Signed into law on July 4, 2025, this act includes provisions for an elective deduction for domestic R&D expenses, reinstatement of 100% first-year bonus depreciation, and repeal of non-U.S. corporations' fiscal year end. This legislation did not have a material impact on the Company's consolidated financial statements as of December 31, 2025.

Insurance & Risk Transfer

Risk Management Framework: Zimmer Biomet manages its exposure to market risks, including foreign currency exchange rates and interest rates, through regular operating and financing activities. The Company utilizes derivative financial instruments solely as risk management tools, not for speculative investment purposes.